104
Participants
Start Date
June 30, 2014
Primary Completion Date
November 17, 2017
Study Completion Date
November 17, 2017
Exendin 9-39
Exendin 9-39 will be administered intravenously (1,200 pmol/kg bolus followed by infusion at 300 pmol/kg/min).
Microlipid
Lipid infusion {66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml).
Placebo
Normal saline infusion will be prepared to match the appearance of Exendin 9-39
Mayo Clinic in Rochester, Rochester
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Mayo Clinic
OTHER